Price$15.91-0.02 (-0.09%)
01:45 PM07:45 PM
News · 26 weeks69-58%
2026-01-182026-07-12
Mix3590d
- Insider21(60%)
- SEC Filings9(26%)
- Earnings2(6%)
- Other2(6%)
- Analyst1(3%)
Latest news
25 items- ANALYSTAnalyst resumed coverage on NovoCure with a new price targetAnalyst resumed coverage of NovoCure with a rating of Neutral and set a new price target of $17.00
- INSIDERChief Human Resources Officer Puri Michal Nath was granted 1,905 units of Ordinary Shares, increasing direct ownership by 0.95% to 203,227 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERChief Executive Officer Leonard Frank X was granted 1,905 units of Ordinary Shares, increasing direct ownership by 0.41% to 461,425 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERGeneral Counsel Ben Arye Barak was granted 1,299 units of Ordinary Shares, increasing direct ownership by 0.54% to 243,752 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Danziger Asaf was granted 268 units of Ordinary Shares, increasing direct ownership by 0.06% to 416,742 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- PRNovocure to Report Second Quarter 2026 Financial ResultsNovocure (NASDAQ:NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 23, to discuss the company’s financial results for the three-month period that ended June 30, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, investor.novocure.com, an
- SECNovoCure Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - NovoCure Ltd (0001645113) (Filer)
- PRNovocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic CancerThe CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant with gemcitabine and nab-paclitaxel Treatment with Optune Pax was also shown to significantly delay patients’ pain progression, helping to preserve quality of life Optune Pax is a first-of-its-kind wearable medical device for the treatment of pancreatic cancer that delivers Tumor Treating Fields, alternating electric fields that cause cancer cell death Novocure (NASDAQ:NVCR) announced today that Optune Pax® has received CE (Conformité Européenne) Mark for the treatment of adult patients with
- SECNovoCure Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - NovoCure Ltd (0001645113) (Filer)
- PRNovocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed GlioblastomaThe Phase 3 TRIDENT trial enrolled patients with glioblastoma prior to the initiation of chemoradiation and evaluated the benefit of initiating Tumor Treating Fields (TTFields) therapy at the start of chemoradiation compared to initiating TTFields therapy in the maintenance phase TRIDENT did not meet its primary endpoint of demonstrating a statistically significant increase in overall survival for patients in the intent-to-treat (ITT) population who initiated TTFields therapy at the start of chemoradiation Results from TRIDENT demonstrated a durable survival benefit for patients in both arms of the trial, no new safety signals were observed, and early initiation of TTFields therapy was
- SECNovoCure Limited filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - NovoCure Ltd (0001645113) (Filer)
- INSIDERDirector Stafford Kristin was granted 11,610 units of Ordinary Shares, increasing direct ownership by 103% to 22,934 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERChief Executive Officer Leonard Frank X sold $614,635 worth of Ordinary Shares (34,273 units at $17.93), decreasing direct ownership by 7% to 459,520 units (SEC Form 4) (withholding tax)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Leung Gabriel was granted 11,610 units of Ordinary Shares, increasing direct ownership by 13% to 101,109 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Ocean Allyson J was granted 11,610 units of Ordinary Shares, increasing direct ownership by 103% to 22,934 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Scannell Timothy J was granted 11,610 units of Ordinary Shares, increasing direct ownership by 81% to 25,898 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Hilleman Jeryl L was granted 11,610 units of Ordinary Shares, increasing direct ownership by 84% to 25,471 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Hung David was granted 11,610 units of Ordinary Shares, increasing direct ownership by 57% to 32,075 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Madden Martin J. was granted 11,610 units of Ordinary Shares, increasing direct ownership by 62% to 30,284 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Vernon W Anthony was granted 11,610 units of Ordinary Shares, increasing direct ownership by 6% to 209,267 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Leung Gabriel sold $46,445 worth of Ordinary Shares (2,945 units at $15.77), decreasing direct ownership by 3% to 89,499 units (SEC Form 4) to satisfy withholding tax4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Stafford Kristin sold $46,445 worth of Ordinary Shares (2,945 units at $15.77), decreasing direct ownership by 21% to 11,324 units (SEC Form 4) (withholding obligation)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Ocean Allyson J sold $46,445 worth of Ordinary Shares (2,945 units at $15.77), decreasing direct ownership by 21% to 11,324 units (SEC Form 4) to cover withholding tax4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Scannell Timothy J sold $46,445 worth of Ordinary Shares (2,945 units at $15.77), decreasing direct ownership by 17% to 14,288 units (SEC Form 4) to satisfy withholding obligation4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Hilleman Jeryl L sold $46,445 worth of Ordinary Shares (2,945 units at $15.77), decreasing direct ownership by 18% to 13,861 units (SEC Form 4) (for withholding tax)4 - NovoCure Ltd (0001645113) (Issuer)
NVCR FAQ
7 questionsWhat does NovoCure Limited do?
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial...Where does NVCR stock trade?
NovoCure Limited (NVCR) is listed on NASDAQ.What sector and industry is NVCR in?
NovoCure Limited operates in the Health Care sector, Medical/Dental Instruments industry.When did NovoCure Limited go public?
NovoCure Limited (NVCR) completed its IPO in 2015.What are analysts saying about NVCR?
NovoCure Limited has had 8 recent analyst actions on file. The most recent action was from Analyst: Neutral with a $1700.00 price target on 2026-07-13. Recent price targets range from $1450.00 to $4500.00.What companies are similar to NVCR?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare NVCR side-by-side with any of them on Quantisnow.How can I track NVCR on Quantisnow?
Quantisnow aggregates NovoCure Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NVCR to receive live email and push alerts on every new disclosure.